

Eugene I Hwang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4274034/publications.pdf>

Version: 2024-02-01

58
papers

1,929
citations

361045

20
h-index

315357

38
g-index

59
all docs

59
docs citations

59
times ranked

3191
citing authors

#	ARTICLE	IF	CITATIONS
1	The current consensus on the clinical management of intracranial ependymoma and its distinct molecular variants. <i>Acta Neuropathologica</i> , 2017, 133, 5-12.	3.9	271
2	Spatial and temporal homogeneity of driver mutations in diffuse intrinsic pontine glioma. <i>Nature Communications</i> , 2016, 7, 11185.	5.8	197
3	Integrated (epi)-Genomic Analyses Identify Subgroup-Specific Therapeutic Targets in CNS Rhabdoid Tumors. <i>Cancer Cell</i> , 2016, 30, 891-908.	7.7	191
4	CNS-PNETs with C19MC amplification and/or LIN28 expression comprise a distinct histogenetic diagnostic and therapeutic entity. <i>Acta Neuropathologica</i> , 2014, 128, 291-303.	3.9	141
5	Long-term efficacy and toxicity of bevacizumab-based therapy in children with recurrent low-grade gliomas. <i>Pediatric Blood and Cancer</i> , 2013, 60, 776-782.	0.8	114
6	Marked Recovery of Vision in Children With Optic Pathway Gliomas Treated With Bevacizumab. <i>JAMA Ophthalmology</i> , 2014, 132, 111.	1.4	100
7	Heterogeneity within the PF-EPN-B ependymoma subgroup. <i>Acta Neuropathologica</i> , 2018, 136, 227-237.	3.9	86
8	Molecular Characterization of Choroid Plexus Tumors Reveals Novel Clinically Relevant Subgroups. <i>Clinical Cancer Research</i> , 2015, 21, 184-192.	3.2	84
9	Pediatric low-grade gliomas: implications of the biologic era. <i>Neuro-Oncology</i> , 2017, 19, now209.	0.6	73
10	A C19MC-LIN28A-MYCN Oncogenic Circuit Driven by Hijacked Super-enhancers Is a Distinct Therapeutic Vulnerability in ETMRs: A Lethal Brain Tumor. <i>Cancer Cell</i> , 2019, 36, 51-67.e7.	7.7	69
11	Pineoblastoma segregates into molecular sub-groups with distinct clinico-pathologic features: a Rare Brain Tumor Consortium registry study. <i>Acta Neuropathologica</i> , 2020, 139, 223-241.	3.9	65
12	Efficacy of Carboplatin and Isotretinoin in Children With High-risk Medulloblastoma. <i>JAMA Oncology</i> , 2021, 7, 1313.	3.4	61
13	Extensive Molecular and Clinical Heterogeneity in Patients With Histologically Diagnosed CNS-PNET Treated as a Single Entity: A Report From the Children's Oncology Group Randomized ACNS0332 Trial. <i>Journal of Clinical Oncology</i> , 2018, 36, 3388-3395.	0.8	58
14	Handheld Optical Coherence Tomography During Sedation in Young Children With Optic Pathway Gliomas. <i>JAMA Ophthalmology</i> , 2014, 132, 265.	1.4	57
15	Implications of new understandings of gliomas in children and adults with NF1: report of a consensus conference. <i>Neuro-Oncology</i> , 2020, 22, 773-784.	0.6	44
16	Clinical and molecular heterogeneity of pineal parenchymal tumors: a consensus study. <i>Acta Neuropathologica</i> , 2021, 141, 771-785.	3.9	44
17	Medulloblastoma rendered susceptible to NK-cell attack by TGF β 2 neutralization. <i>Journal of Translational Medicine</i> , 2019, 17, 321.	1.8	32
18	Treatment of pediatric cerebral radiation necrosis: a systematic review. <i>Journal of Neuro-Oncology</i> , 2016, 130, 141-148.	1.4	26

#	ARTICLE	IF	CITATIONS
19	A phase I trial of the CDK 4/6 inhibitor palbociclib in pediatric patients with progressive brain tumors: A Pediatric Brain Tumor Consortium study (PBTC042). <i>Pediatric Blood and Cancer</i> , 2021, 68, e28879.	0.8	24
20	Case-based review: pediatric medulloblastoma. <i>Neuro-Oncology Practice</i> , 2017, 4, 138-150.	1.0	22
21	Therapeutic implications of improved molecular diagnostics for rare CNS embryonal tumor entities: results of an international, retrospective study. <i>Neuro-Oncology</i> , 2021, 23, 1597-1611.	0.6	22
22	The current landscape of immunotherapy for pediatric brain tumors. <i>Nature Cancer</i> , 2022, 3, 11-24.	5.7	21
23	¹²⁵ I-Np73/ETS2 complex drives glioblastoma pathogenesis—targeting downstream mediators by rebastinib prolongs survival in preclinical models of glioblastoma. <i>Neuro-Oncology</i> , 2020, 22, 345-356.	0.6	20
24	A pediatric brain tumor consortium phase II trial of capecitabine rapidly disintegrating tablets with concomitant radiation therapy in children with newly diagnosed diffuse intrinsic pontine gliomas. <i>Pediatric Blood and Cancer</i> , 2018, 65, e26832.	0.8	13
25	A Phase I and Surgical Study of Ribociclib and Everolimus in Children with Recurrent or Refractory Malignant Brain Tumors: A Pediatric Brain Tumor Consortium Study. <i>Clinical Cancer Research</i> , 2021, 27, 2442-2451.	3.2	13
26	IMMU-09. OUTCOME OF PATIENTS WITH RECURRENT DIFFUSE INTRINSIC PONTINE GLIOMA (DIPG) TREATED WITH PEMBROLIZUMAB (ANTI-PD-1): A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY (PBTC045). <i>Neuro-Oncology</i> , 2018, 20, i100-i100.	0.6	11
27	MRI Features of Histologically Diagnosed Supratentorial Primitive Neuroectodermal Tumors and Pineoblastomas in Correlation with Molecular Diagnoses and Outcomes: A Report from the Children's Oncology Group ACNS0332 Trial. <i>American Journal of Neuroradiology</i> , 2019, 40, 1796-1803.	1.2	11
28	Molecularly Targeted Agents in the Therapy of Pediatric Brain Tumors. <i>Paediatric Drugs</i> , 2020, 22, 45-54.	1.3	7
29	Pediatric diffuse leptomeningeal glioneuronal tumor: Two clinical cases of successful targeted therapy. <i>Pediatric Blood and Cancer</i> , 2020, 67, e28478.	0.8	7
30	Harmonization of postmortem donations for pediatric brain tumors and molecular characterization of diffuse midline gliomas. <i>Scientific Reports</i> , 2020, 10, 10954.	1.6	7
31	The experience of successful treatment of <i>ETV6-NTRK3</i> -positive infant glioblastoma with entrectinib. <i>Neuro-Oncology Advances</i> , 2021, 3, vdab022.	0.4	7
32	Histological and molecular analysis of a progressive diffuse intrinsic pontine glioma and synchronous metastatic lesions: a case report. <i>Oncotarget</i> , 2017, 8, 42837-42842.	0.8	7
33	Considerations when treating high-grade pediatric glioma patients with immunotherapy. <i>Expert Review of Neurotherapeutics</i> , 2021, 21, 205-219.	1.4	5
34	PDCT-07. FEASIBILITY TRIAL OF TTFIELDS (TUMOR TREATING FIELDS) FOR CHILDREN WITH RECURRENT OR PROGRESSIVE SUPRATENTORIAL HIGH-GRADE GLIOMA (HGG) AND EPENDYMOMA: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048. <i>Neuro-Oncology</i> , 2018, 20, vi201-vi202.	0.6	4
35	EMBR-15. DIAGNOSTIC RE-EVALUATION AND POOLED CLINICAL DATA ANALYSIS OF PATIENTS WITH PREVIOUS DIAGNOSIS OF CNS-PNET. <i>Neuro-Oncology</i> , 2018, 20, i72-i72.	0.6	4
36	Two clinically distinct cases of infant hemispheric glioma carrying <i>ZCCHC8:ROS1</i> fusion and responding to entrectinib. <i>Neuro-Oncology</i> , 2022, 24, 1029-1031.	0.6	4

#	ARTICLE	IF	CITATIONS
37	Immunotherapy Approaches for Pediatric CNS Tumors and Associated Neurotoxicity. <i>Pediatric Neurology</i> , 2020, 107, 7-15.	1.0	2
38	MBCL-16. EFFICACY OF CARBOPLATIN GIVEN CONCOMITANTLY WITH RADIATION AND ISOTRETINOIN AS A PRO-APOPTOTIC AGENT IN MAINTENANCE THERAPY IN HIGH-RISK MEDULLOBLASTOMA: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP. <i>Neuro-Oncology</i> , 2020, 22, iii391-iii391.	0.6	2
39	QOLP-24. PATIENTS'/PARENTS' EXPERIENCES OF RECEIVING OPTUNE DELIVERED TUMOR TREATMENT FIELDS: A PEDIATRIC BRAIN TUMOR CONSORTIUM STUDY: PBTC-048. <i>Neuro-Oncology</i> , 2019, 21, vi202-vi203.	0.6	1
40	IMMU-19. Outcomes of Pediatric Patients with High-Risk CNS Tumors Treated with Multi-tumor associated antigen specific T cell (TAA-T) therapy: the ReMIND trial. <i>Neuro-Oncology</i> , 2022, 24, i85-i86.	0.6	1
41	Experimental Therapeutic Trial Design for Pediatric Brain Tumors. <i>Journal of Child Neurology</i> , 2016, 31, 1421-1432.	0.7	0
42	EPID-08. THE CURRENT LANDSCAPE OF THERAPEUTIC CLINICAL TRIALS IN PEDIATRIC BRAIN TUMORS: A REVIEW OF CLINICALTRIALS.GOV. <i>Neuro-Oncology</i> , 2018, 20, i81-i82.	0.6	0
43	CRAN-16. IMPORTANCE OF SURGICAL INTERVENTION IN RECOVERY OF VISUAL FUNCTION IN A TEENAGER WITH AN ACIDOPHILIC STEM CELL ADENOMA. <i>Neuro-Oncology</i> , 2018, 20, i39-i40.	0.6	0
44	EMBR-01. MOLECULAR AND CLINICAL HETEROGENEITY IN HISTOLOGICALLY-DIAGNOSED CNS-PNET PATIENTS PROSPECTIVELY TREATED AS A SINGLE ENTITY: A REPORT FROM THE CHILDREN'S ONCOLOGY GROUP ACNS0332 TRIAL. <i>Neuro-Oncology</i> , 2018, 20, i68-i69.	0.6	0
45	EMBR-17. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOR CONSORTIUM. <i>Neuro-Oncology</i> , 2018, 20, i72-i73.	0.6	0
46	GENE-06. DISTINCT MOLECULAR SUBGROUPS OF TUMORS OF THE PINEAL REGION CORRELATE WITH CLINICAL PARAMETERS AND GENETIC ALTERATIONS. <i>Neuro-Oncology</i> , 2019, 21, ii81-ii82.	0.6	0
47	PDTM-24. PINEOBLASTOMA SEGREGATES INTO MOLECULAR SUBTYPES WITH DISTINCT CLINICOPATHOLOGIC FEATURES: REPORT FROM THE RARE BRAIN TUMOUR CONSORTIUM. <i>Neuro-Oncology</i> , 2019, 21, vi192-vi192.	0.6	0
48	EMBR-08. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON "HEAD START" CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2021, 23, i7-i7.	0.6	0
49	EMBR-03. PINEOBLASTOMA: A POOLED OUTCOME STUDY OF NORTH AMERICAN AND AUSTRALIAN THERAPEUTIC DATA. <i>Neuro-Oncology</i> , 2021, 23, i6-i6.	0.6	0
50	EPCT-05. A PHASE I TRIAL OF THE CDK 4/6 INHIBITOR PALBOCICLIB IN PEDIATRIC PATIENTS WITH PROGRESSIVE OR REFRACTORY CNS TUMORS: A PEDIATRIC BRAIN TUMOR CONSORTIUM (PBTC) STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii304-iii304.	0.6	0
51	MBCL-13. CORRELATION OF HISTOPATHOLOGY, CHROMOSOMAL MICROARRAY, AND NANOSTRING BASED 22-GENE ASSAY FOR MEDULLOBLASTOMA SUBGROUP ASSIGNMENT ON "HEAD START" CLINICAL TRIAL. <i>Neuro-Oncology</i> , 2020, 22, iii390-iii390.	0.6	0
52	EPCT-16. A PHASE IB STUDY OF PTC596 IN CHILDREN WITH NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE GLIOMA AND HIGH GRADE GLIOMA. <i>Neuro-Oncology</i> , 2020, 22, iii306-iii307.	0.6	0
53	IMMU-08. TeMATCH PROTOCOL: PHASE II STUDY OF EX-VIVO EXPANDED AUTOLOGOUS TUMOR SPECIFIC LYMPHOCYTE TRANSFER (X-ALT) + TOTAL TUMOR RNA DC VACCINE (TT-RNA DC) DURING RECOVERY FROM MYELOABLATIVE CHEMOTHERAPY (MAC) AND PERIPHERAL BLOOD STEM CELL (PBSC) RESCUE OR NON-MYELOABLATIVE CHEMOTHERAPY (NMAC) AND PBSC IN PATIENTS (PTS) WITH RECURRENT PNET (R-PNET). <i>Neuro-Oncology</i> , 2020, 22, iii361-iii361.	0.6	0
54	EPCT-17. A PHASE I AND SURGICAL STUDY OF RIBOCICLIB AND EVEROLIMUS IN CHILDREN WITH RECURRENT OR REFRACTORY MALIGNANT BRAIN TUMORS: PEDIATRIC BRAIN TUMOR CONSORTIUM INTERIM REPORT. <i>Neuro-Oncology</i> , 2020, 22, iii307-iii307.	0.6	0

#	ARTICLE	IF	CITATIONS
55	ETMR-21. META-ANALYSIS OF PINEAL REGION TUMOURS DEMONSTRATES MOLECULAR SUBGROUPS WITH DISTINCT CLINICO-PATHOLOGICAL FEATURES: A CONSENSUS STUDY. <i>Neuro-Oncology</i> , 2020, 22, iii327-iii327.	0.6	0
56	LGG-26. DIFFUSE LEPTOMENINGEAL GLIONEURONAL TUMOR (DLGNT) IN CHILDREN: DIFFERENT CLINICAL PRESENTATIONS AND OUTCOMES. <i>Neuro-Oncology</i> , 2020, 22, iii371-iii371.	0.6	0
57	HGG-11. Clinical characteristics and clinical evolution of a large cohort of pediatric patients with primary central nervous system (CNS) tumors and tropomyosin receptor kinase (TRK) fusion.. <i>Neuro-Oncology</i> , 2022, 24, i61-i62.	0.6	0
58	EPCT-05. Phase Ib study of unesbulin (PTC596) in children with newly diagnosed diffuse intrinsic pontine glioma (DIPG) and high-grade glioma (HGG): A report from the COllaborative Network for NEuro-Oncology Clinical Trials (CONNECT). <i>Neuro-Oncology</i> , 2022, 24, i36-i36.	0.6	0